Centre Hospitalier William Morey

The center is at the forefront of research in Multiple Myeloma, focusing on innovative treatment regimens for newly diagnosed and relapsed cases. The integration of novel therapeutic agents such as isatuximab and daratumumab with established drugs like lenalidomide and dexamethasone is being explored to enhance patient outcomes.

• Isatuximab plus lenalidomide and dexamethasone
• Daratumumab, lenalidomide, and dexamethasone
• Advanced relapsed/refractory multiple myeloma therapies

These studies aim to improve Minimal Residual Disease rates and overall survival, offering hope for better management of this challenging condition.

Research in Autoimmune Hemolytic Anemia (AIHA) is focused on the prevention of Venous Thromboembolic Disease through prolonged anticoagulation strategies. The efficacy of combining heparin therapy with oral anticoagulants is under investigation to reduce thromboembolic events in patients with warm-type AIHA.

• Prolonged anticoagulation strategies
• Prevention of venous thromboembolism

This research is pivotal in enhancing the quality of life and reducing complications for patients with AIHA.

The center is conducting a comparative study on the treatment of early syphilis, evaluating the efficacy of doxycycline versus benzathine penicillin G (BPG). This research aims to establish non-inferiority of doxycycline, potentially offering a more accessible treatment option.

• Doxycycline vs BPG
• Non-inferiority trials

Such studies are crucial in optimizing treatment protocols and improving patient compliance.

In the realm of ER+/HER2- metastatic breast cancer, the center is exploring the combination of palbociclib with endocrine therapies. The focus is on detecting ESR1 mutations through circulating tumor DNA and adjusting treatment accordingly to enhance therapeutic efficacy.

• Palbociclib and endocrine therapy
• ESR1 mutation detection

This research is instrumental in personalizing treatment and improving outcomes for patients with metastatic breast cancer.

The center is advancing treatment strategies for metastatic renal cell carcinoma (mRCC) by comparing immune checkpoint inhibitors with VEGFR TKI combinations. The research aims to improve survival outcomes based on PDL1 stratification.

• Immune checkpoint inhibitors
• VEGFR TKI combinations

These studies are pivotal in refining therapeutic approaches and enhancing survival rates for mRCC patients.

Research on MMR deficient endometrial cancer is focused on comparing chemotherapy with dostarlimab in advanced/metastatic settings. The goal is to improve progression-free survival and overall outcomes for patients.

• Dostarlimab vs chemotherapy
• Progression-free survival

This research is crucial in developing more effective first-line treatments for endometrial cancer.

The center is evaluating the long-term efficacy of colchicine and ticagrelor in reducing recurrent major vascular events. This research encompasses a range of conditions including stroke, ischemic heart disease, and atherosclerosis.

• Colchicine and ticagrelor therapy
• Reduction of vascular events

These studies are vital in preventing recurrent cardiovascular events and improving patient outcomes.

Research is being conducted on the efficacy of the nonavalent HPV vaccine in treating difficult-to-treat palmar or plantar warts. The study aims to achieve complete remission in patients who have failed previous treatments.

• Nonavalent HPV vaccine
• Remission of palmar/plantar warts

This research is significant in providing new therapeutic options for patients with persistent warts.